Présentation de l'entreprise
ABIVAX Société Anonyme, identified by the ticker ABVX, operates as a clinical-stage biotechnology entity dedicated to developing therapeutics that utilize the body's inherent regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. The company functions within the broader healthcare sector, specifically targeting the specialized industry of biotechnology where innovation in drug candidates like obefazimod, currently in Phase 3 clinical development, is central to its operational strategy. As of the latest available data, the enterprise holds a market capitalization of $9.69B, generates annual revenue of $4.57M, and employs a workforce of 69 individuals. The disparity between the substantial market capitalization of $9.69B and the relatively modest annual revenue of $4.57M indicates that the market is valuing the company primarily on the potential future success of its lead drug candidates and intellectual property pipeline rather than on current operational cash flows or established commercial sales. This valuation structure is typical for clinical-stage biotechnology firms where significant investment is made in research and development before a product achieves commercialization and generates profit.
Santé financière
The company reported a revenue of $4.57M over the trailing twelve months, yet recorded a net income of $-336,102,016 and an EBITDA of $-244,983,008, revealing a cost structure where expenses vastly exceed top-line earnings. This significant gap between revenue and net income highlights the intense capital expenditure required for clinical trials and research activities inherent to the biotechnology industry, resulting in a profit margin of 0.0%. The free cash flow stands at $-118,316,624, which signifies that the company is burning cash to fund its development programs rather than generating liquidity from operations. Despite the negative operating margin of -3743.4%, the company maintains a gross margin of 100.0%, suggesting that the cost of goods sold is negligible relative to sales, a common characteristic in the pharmaceutical sector where manufacturing costs are often low compared to R&D. On the balance sheet, the company holds $530.38M in cash against $32.09M in debt, creating a liquidity buffer that appears robust despite the high debt-to-equity ratio of 7.05, which reflects the accounting treatment of preferred shares or similar instruments rather than traditional leverage. The current ratio of 8.75 demonstrates a strong short-term liquidity position, indicating that the company possesses ample current assets to cover its current liabilities. However, the return on equity is -135.6% and the return on assets is -39.0%, metrics that reveal that management effectiveness in generating returns on shareholder capital and assets is currently negative due to the heavy investment phase of the business model.
Évaluation de la valorisation
The trailing P/E ratio is not available, while the forward P/E is listed at -41.85, implying that the market expects earnings to remain negative or that the valuation is being driven by non-earnings multiples typical of pre-revenue or loss-making biotech assets. The price-to-book ratio stands at 17.73, indicating a substantial market premium over the company's book value, which suggests investors are pricing in high growth expectations rather than current asset liquidation values. Alternative valuation metrics such as the price-to-sales ratio of 2119.27 and the EV/EBITDA of -36.42 further illustrate that the stock is valued entirely on future revenue potential rather than current profitability or earnings power. The 52-week high is $148.83 and the 52-week low is $4.77, meaning the current price sits at a level significantly below the annual peak but also well above the floor, reflecting high volatility. The beta value of -0.10 is an anomaly that suggests the stock price moves inversely to the broader market or that the calculation methodology for this specific small-cap stock yields a negative correlation coefficient, indicating unique risk characteristics unrelated to standard market movements. These valuation figures collectively suggest that the stock price is highly sensitive to clinical trial outcomes and regulatory approvals rather than traditional financial stability indicators.
Growth & Income
The revenue growth year-over-year is -55.4%, while earnings growth is not available due to the negative earnings history, indicating that the company is contracting in terms of sales or that the revenue base is too volatile to calculate a consistent growth trajectory. Since the earnings are negative, there is no dividend yield or payout ratio to assess, as the company retains all resources to fund its clinical operations rather than distributing income to shareholders. Consequently, the company reinvests its remaining cash reserves and potential future earnings into growth initiatives such as advancing obefazimod through Phase 3 clinical development rather than paying dividends. The overall growth and income profile is characterized by a contraction in revenue coupled with significant cash burn, reflecting the high-risk, high-reward nature of clinical-stage biotechnology companies that rely on external capital or internal cash reserves to sustain operations until product approval.